Solexa, Inc. 4/A
4/A · Solexa, Inc. · Filed Feb 1, 2007
Insider Transaction Report
Form 4/AAmended
Solexa, Inc.SLXA
Rubinstein Linda M
VP & Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2007-01-26−82,250→ 0 totalExercise: $6.11Exp: 2015-06-03→ Common Stock (82,250 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2007-01-26−17,188→ 0 totalExercise: $5.97Exp: 2015-09-06→ Common Stock (17,188 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2007-01-26−59,375→ 0 totalExercise: $8.60Exp: 2016-02-02→ Common Stock (59,375 underlying)
Footnotes (3)
- [F1]This option, which provided for vesting monthly and ratably over the 48 month period beginning on March 22, 2005, was assumed by Illumina, Inc. in connection with the merger with Solexa, Inc. and replaced with an option to purchase 28,294 shares at an exercise price of $17.76 per share. In connection with the closing of the merger on January 26, 2007, the vesting and exercisability of this option was accelerated by 2 years as provided in the employment agreement between the Issuer and the Reporting Person.
- [F2]This option, which provided for vesting monthly and ratably over the 48 month period beginning on September 6, 2005, was assumed by Illumina, Inc. in connection with the merger with Solexa, Inc. and replaced with an option to purchase 5,913 shares at an exercise price of $17.35 per share. In connection with the closing of the merger on January 26, 2007, the vesting and exercisability of this option was accelerated by 2 years as provided in the employment agreement between the Issuer and the Reporting Person.
- [F3]This option, which provided for vesting monthly and ratably over the 48 month period beginning on February 2, 2006, was assumed by Illumina, Inc. in connection with the merger with Solexa, Inc. and replaced with an option to purchase 20,426 shares at an exercise price of $25.00 per share. In connection with the closing of the merger on January 26, 2007, the vesting and exercisability of this option was accelerated by 2 years as provided in the employment agreement between the Issuer and the Reporting Person.